We are live on ! Find out more
PVLA

Palvella Therapeutics
PVLA

95 hedge funds and large institutions have $85.9M invested in Palvella Therapeutics in 2020 Q1 according to their latest regulatory filings, with 16 funds opening new positions, 30 increasing their positions, 31 reducing their positions, and 18 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more funds holding in top 10

Funds holding in top 10: 1 → 2 (+1)

0.03% more ownership

Funds ownership: 0.81% → 0.84% (+0.03%)

3% less repeat investments, than reductions

Existing positions increased: 30 | Existing positions reduced: 31

2% less funds holding

Funds holding: 97 → 95 (-2)

11% less first-time investments, than exits

New positions opened: 16 | Existing positions closed: 18

33% less capital invested

Capital invested by funds: $129M → $85.9M (-$42.6M)

Holders
95
Holders Change
-2
Holders Change %
-2.06%
% of All Funds
2.09%
Holding in Top 10
2
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+100%
% of All Funds
0.04%
New
16
Increased
30
Reduced
31
Closed
18
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
CA
Corriente Advisors
Texas
+$5.61M
2
WP
Woodline Partners
California
+$3.29M
3
SB
Samsara BioCapital
California
+$2.89M
4
ACM
Aquilo Capital Management
California
+$1.92M
5
BI
BVF Inc
California
+$1.65M

Top Sellers

Rank Fund Capital Flow
1
EC
EcoR1 Capital
California
-$7.15M
2
OAM
Oxford Asset Management
United Kingdom
-$1.3M
3
Morgan Stanley
Morgan Stanley
New York
-$1.29M
4
N
Nuveen
North Carolina
-$719K
5
MWNA
Marshall Wace North America
New York
-$701K
Name Holding Trade Value Shares
Change 		Change in
Stake
CHAM
26
Clear Harbor Asset Management
Connecticut
$496K +$20.9K +83 +3%
Cerity Partners
27
Cerity Partners
New York
$434K – – –
FDCDDQ
28
Federation des caisses Desjardins du Quebec
Quebec, Canada
$415K -$59.7K -237 -10%
AQR Capital Management
29
AQR Capital Management
Connecticut
$412K +$516K +2,046 +956%
N
30
Nuveen
North Carolina
$394K -$719K -2,855 -57%
GCP
31
GSA Capital Partners
United Kingdom
$353K -$127K -505 -21%
SO
32
STRS Ohio
Ohio
$318K – – –
Bank of New York Mellon
33
Bank of New York Mellon
New York
$303K -$3.53K -14 -0.8%
Wells Fargo
34
Wells Fargo
California
$291K +$111K +441 +38%
Charles Schwab
35
Charles Schwab
California
$267K +$3.53K +14 +1%
VC
36
Voss Capital
Texas
$245K +$15.9K +63 +3%
Massachusetts Financial Services
37
Massachusetts Financial Services
Massachusetts
$234K +$51.2K +203 +19%
Two Sigma Advisers
38
Two Sigma Advisers
New York
$233K -$18.6K -74 -5%
Dimensional Fund Advisors
39
Dimensional Fund Advisors
Texas
$219K -$167K -661 -35%
SPC
40
Sigma Planning Corp
Michigan
$216K +$298K +1,184 New
Creative Planning
41
Creative Planning
Kansas
$205K -$2.52K -10 -0.9%
6CM
42
683 Capital Management
New York
$205K – – –
RCG
43
Rock Creek Group
District of Columbia
$194K +$15.9K +63 +6%
Squarepoint
44
Squarepoint
New York
$186K +$116K +462 +83%
CS
45
Credit Suisse
Switzerland
$175K +$242K +959 New
UBS Group
46
UBS Group
Switzerland
$173K +$55.2K +219 +30%
California State Teachers Retirement System (CalSTRS)
47
California State Teachers Retirement System (CalSTRS)
California
$162K +$2.52K +10 +1%
RJA
48
Raymond James & Associates
Florida
$162K +$8.06K +32 +4%
RhumbLine Advisers
49
RhumbLine Advisers
Massachusetts
$144K – – –
Los Angeles Capital Management
50
Los Angeles Capital Management
California
$140K +$194K +768 New
1
2
3 4 5

PVLA Hedge Fund Activity: Q1 2020 in Review

95 of the 4,538 institutional investors tracked by Wall St. Rank reported a position in Palvella Therapeutics (PVLA) for Q1 2020, worth a combined $85.9M — down 33% from $129M a quarter earlier.

Sellers outnumbered buyers: 18 funds closed out of PVLA and 16 opened new positions — a net loss of 2 holders — while 31 trimmed existing stakes and 30 added.

The largest buyer was Corriente Advisors, opening a new position worth an estimated $5.61M. The largest seller was EcoR1 Capital, cutting an estimated $7.15M.

  • 95 institutional investors held Palvella Therapeutics (PVLA) as of Q1 2020, down from 97 in Q4 2019.
  • Funds reported $85.9M of Palvella Therapeutics stock for Q1 2020, down 33% quarter-over-quarter.
  • 16 funds opened new Palvella Therapeutics positions in Q1 2020 and 18 closed out, a net change of -2 holders.
  • The largest Palvella Therapeutics buyer in Q1 2020 was Corriente Advisors, an estimated $5.61M added.
  • The largest Palvella Therapeutics seller in Q1 2020 was EcoR1 Capital, an estimated $7.15M sold.

Based on aggregated 13F filings for Q1 2020.